Takayuki Motoki

Okayama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Safety and Efficacy of a Well-Fitting Brassiere after Breast Reconstruction: A Qualitative Study.

Safety and Efficacy of a Well-Fitting Brassiere after Breast Reconstruction: A Qualitative Study.

Journal: Acta medica Okayama

Published: February 27, 2023

A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.

A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.

Journal: Internal medicine (Tokyo, Japan)

Published: November 16, 2020

A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.

A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.

Journal: Acta medica Okayama

Published: April 21, 2018

Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

Journal: Breast cancer research and treatment

Published: April 12, 2017

Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.

Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.

Journal: BMC cancer

Published: March 14, 2017

A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.

A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.

Journal: Acta medica Okayama

Published: October 26, 2016

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

Journal: Oncotarget

Published: June 29, 2016

A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.

A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.

Journal: Cancer chemotherapy and pharmacology

Published: May 22, 2016

Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery.

Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery.

Journal: Breast cancer (Tokyo, Japan)

Published: January 14, 2016

Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.

Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.

Journal: Acta medica Okayama

Published: December 23, 2015

N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women.

N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women.

Journal: Breast cancer (Tokyo, Japan)

Published: December 11, 2015

Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.

Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.

Journal: Acta medica Okayama

Published: October 23, 2015

Showing 1-12 of 19

Last Updated: 09/26/2026